Also trades as: 0K1R.L (LSE) · $vol 0M
VRDN NASDAQ
Viridian Therapeutics, Inc.
1W: +7.4%
1M: +17.1%
3M: +21.2%
YTD: -21.5%
1Y: +8.7%
3Y: +108.0%
5Y: +43.9%
$24.09
+0.75 (+3.21%)
Pre-Market: $22.88 (-1.21, -5.04%)
Weekly Expected Move ±9.1%
$18
$20
$22
$24
$26
Credit Risk of going bust: higher than 61% of companies Debt: 8.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.73B.
Distance to default 4.13 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.73B.
Distance to default 4.13 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships10
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-04-26
Earliest Filing
2025-10-23
Latest Filing
partner: 7
customer: 3
Counterparties (Filed by VRDN)
10 relationshipsCompanies named in VRDN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Underwriter in the offering of common stock | 2025-10-23 | View |
| Leerink Partners LLC | — | partner | Underwriter in the offering of common stock | 2025-10-23 | View |
| Evercore Group L.L.C. | EVR | partner | Underwriter in the offering of common stock | 2025-10-23 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Underwriter in the offering of common stock | 2025-10-23 | View |
| Kissei Pharmaceuticals, Inc. | — | customer | Counterparty to purchase and sale agreement providing upfront payment | 2025-10-23 | View |
| DRI Health Acquisition LP | — | customer | Counterparty to purchase and sale agreement providing upfront payment and milestones | 2025-10-23 | View |
| DRI Healthcare Acquisitions LP | — | customer | Purchased rights to certain revenue streams in the U.S. from Viridian Therapeutics, Inc. in exchange for up to $300 mill | 2025-10-20 | View |
| Kissei Pharmaceutical Co., Ltd. | — | partner | Entered into a Collaboration and License Agreement for exclusive development and commercialization of monoclonal antibod | 2025-07-30 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Open Market Sale Agreement | 2025-03-04 | View |
| Jefferies LLC | JEF | partner | Agent for Open Market Sale Agreement | 2021-04-26 | View |
Mentioned As Counterparty
1 mentionsOther companies that named VRDN in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-29 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-03 | Shareholder Vote | View | |
| 2026-05-28 | Termination of Agreement | View | |
| 2026-05-26 | Material Agreement | Agreement | View |
| 2026-05-11 | Material Agreement; Financial Obligation; Other Events; Exhibits | Agreement | View |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-05-05 | Regulation FD; Exhibits | View | |
| 2026-03-30 | Regulation FD; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-23 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-10-21 | Results of Operations and Financial Condition | View | |
| 2025-10-20 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-30 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-06-24 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-07 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR